The European Medicines Agency is considering an application to approve the Sputnik V vaccine, developed by Moscow’s Gamaleya Institute, to protect the EU against coronavirus infection, the team behind the jab says.
In a Tweet on Wednesday, the developers of the Russian-made formula said they had met with the European Union’s (EU) healthcare regulator just one day prior. According to the Russian Direct Investment Fund, which financed the vaccine, they “filed for Sputnik V’s registration in the EU and expect it to be reviewed in February. Based on these reviews, the EMA will decide on authorization of Sputnik V for the EU.” While the process of approving a vaccine usually takes weeks, it has been expedited during the pandemic.
Continue reading https://on.rt.com/azw3